An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.
EVERSANA announced a partnership with the Institute for Clinical and Economic Review (ICER) to advance standards for the usage of transparent, replicable and robust indirect treatment comparisons in health technology assessments.
EVERSANA, a leading independent provider of global commercial services to the life sciences industry, announced the appointment of Brigham Hyde, Ph.D. to President, Data & Analytics (D&A).
As the J.P. Morgan Healthcare Conference entered the final day for 2020, a few topics rose to the top as trending, including the relative lack of big deals.
Biogen Inc. revived plans to seek U.S. approval for the experimental Alzheimer’s treatment aducanumab, surprising investors.
The World Health Organization said eradicating malaria is biologically feasible and a lofty aim, but the focus for now should be getting the funds, tools and political will to control the mosquito-borne disease.
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical teamed up to study the most common type of metastatic colorectal cancer.
AstraZeneca’s Calquence (acalabrutinib) hit the mark in a Phase III trial of previously treated patients with chronic lymphocytic leukemia (CLL).
Shares of Evoke Pharma plunged more than 40 percent after the company announced the U.S. FDA issued a Complete Response Letter regarding the gastroparesis treatment Gimotti.
Megaputer Intelligence is hosting a series of live webinars related to data analysis applications for pharmaceutical and life sciences companies beginning on February 6, 2019, and continuing weekly through April 2019.